25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives

Jessica Lohrke, Thomas Frenzel, Jan Endrikat, Filipe Caseiro Alves, Thomas M. Grist, Meng Law, Jeong Min Lee, Tim Leiner, Kun Cheng Li, Konstantin Nikolaou, Martin R. Prince, Hans H. Schild, Jeffrey C. Weinreb, Kohki Yoshikawa, Hubertus Pietsch

Research output: Contribution to journalReview article

88 Citations (Scopus)

Abstract

Abstract: In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives. Funding: Bayer HealthCare.

Original languageEnglish
Pages (from-to)1-28
Number of pages28
JournalAdvances in Therapy
Volume33
Issue number1
DOIs
StatePublished - 1 Jan 2016

Fingerprint

Magnetic Resonance Imaging
Contrast Media
Gadolinium DTPA
Diagnostic Imaging
Urogenital System
Lymphatic System
Musculoskeletal System
Disease Management
Breast
Central Nervous System
History
Technology
Delivery of Health Care
Lung
Skin

Keywords

  • Body imaging
  • Contrast enhancement
  • Gadolinium
  • MRI
  • Multimodality imaging
  • Relaxivity

Cite this

Lohrke, J., Frenzel, T., Endrikat, J., Alves, F. C., Grist, T. M., Law, M., ... Pietsch, H. (2016). 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Advances in Therapy, 33(1), 1-28. https://doi.org/10.1007/s12325-015-0275-4
Lohrke, Jessica ; Frenzel, Thomas ; Endrikat, Jan ; Alves, Filipe Caseiro ; Grist, Thomas M. ; Law, Meng ; Lee, Jeong Min ; Leiner, Tim ; Li, Kun Cheng ; Nikolaou, Konstantin ; Prince, Martin R. ; Schild, Hans H. ; Weinreb, Jeffrey C. ; Yoshikawa, Kohki ; Pietsch, Hubertus. / 25 Years of Contrast-Enhanced MRI : Developments, Current Challenges and Future Perspectives. In: Advances in Therapy. 2016 ; Vol. 33, No. 1. pp. 1-28.
@article{134a8b232ee344deb58b106e917069ea,
title = "25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives",
abstract = "Abstract: In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist{\circledR}), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives. Funding: Bayer HealthCare.",
keywords = "Body imaging, Contrast enhancement, Gadolinium, MRI, Multimodality imaging, Relaxivity",
author = "Jessica Lohrke and Thomas Frenzel and Jan Endrikat and Alves, {Filipe Caseiro} and Grist, {Thomas M.} and Meng Law and Lee, {Jeong Min} and Tim Leiner and Li, {Kun Cheng} and Konstantin Nikolaou and Prince, {Martin R.} and Schild, {Hans H.} and Weinreb, {Jeffrey C.} and Kohki Yoshikawa and Hubertus Pietsch",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s12325-015-0275-4",
language = "English",
volume = "33",
pages = "1--28",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer International Publishing AG",
number = "1",

}

Lohrke, J, Frenzel, T, Endrikat, J, Alves, FC, Grist, TM, Law, M, Lee, JM, Leiner, T, Li, KC, Nikolaou, K, Prince, MR, Schild, HH, Weinreb, JC, Yoshikawa, K & Pietsch, H 2016, '25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives', Advances in Therapy, vol. 33, no. 1, pp. 1-28. https://doi.org/10.1007/s12325-015-0275-4

25 Years of Contrast-Enhanced MRI : Developments, Current Challenges and Future Perspectives. / Lohrke, Jessica; Frenzel, Thomas; Endrikat, Jan; Alves, Filipe Caseiro; Grist, Thomas M.; Law, Meng; Lee, Jeong Min; Leiner, Tim; Li, Kun Cheng; Nikolaou, Konstantin; Prince, Martin R.; Schild, Hans H.; Weinreb, Jeffrey C.; Yoshikawa, Kohki; Pietsch, Hubertus.

In: Advances in Therapy, Vol. 33, No. 1, 01.01.2016, p. 1-28.

Research output: Contribution to journalReview article

TY - JOUR

T1 - 25 Years of Contrast-Enhanced MRI

T2 - Developments, Current Challenges and Future Perspectives

AU - Lohrke, Jessica

AU - Frenzel, Thomas

AU - Endrikat, Jan

AU - Alves, Filipe Caseiro

AU - Grist, Thomas M.

AU - Law, Meng

AU - Lee, Jeong Min

AU - Leiner, Tim

AU - Li, Kun Cheng

AU - Nikolaou, Konstantin

AU - Prince, Martin R.

AU - Schild, Hans H.

AU - Weinreb, Jeffrey C.

AU - Yoshikawa, Kohki

AU - Pietsch, Hubertus

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Abstract: In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives. Funding: Bayer HealthCare.

AB - Abstract: In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives. Funding: Bayer HealthCare.

KW - Body imaging

KW - Contrast enhancement

KW - Gadolinium

KW - MRI

KW - Multimodality imaging

KW - Relaxivity

UR - http://www.scopus.com/inward/record.url?scp=84955271472&partnerID=8YFLogxK

U2 - 10.1007/s12325-015-0275-4

DO - 10.1007/s12325-015-0275-4

M3 - Review article

C2 - 26809251

AN - SCOPUS:84955271472

VL - 33

SP - 1

EP - 28

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 1

ER -